Press-release for stocks for abbv

| 0.7% | O: 0.06% H: 1.27% C: -0.44%
LLY | News S | $323.0 1.69% 0.07% |

| -0.19% | O: 0.99% H: 0.0% C: 0.0%
SNY | News | $52.67 1.02% -0.32% |

| -0.08% | O: -0.27% H: 0.0% C: 0.0%
pharma

CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis
Published: 2022-06-27 (Crawled : 07:00) - prnewswire.com
ABBV | $154.14 1.08% -1.03% |

| 2.26% | O: 1.55% H: 0.0% C: 0.0%
rinvoq treatment active for chmp approval

Irritable Bowel Syndrome Treatment Market to Surpass US$ 3,902.9 Million by 2030 - Coherent Market Insights
Published: 2022-06-24 (Crawled : 18:00) - prnewswire.com
ALPMY | News | $15.75 -2.42% |

Manufacturing

| -1.07% | O: 4.33% H: 0.0% C: -2.44%
ALPMF | News | $16.71 5.56% |

| 6.07% | O: 0.99% H: 0.0% C: -0.5%
ABBV | $154.14 1.08% -1.03% |

| 3.86% | O: 1.57% H: 0.0% C: 0.0%
BHC | News A | $8.51 -3.62% 0.0% |

| 17.06% | O: 5.78% H: 13.91% C: 13.78%
IRWD | $11.72 1.65% 1.45% |

| 6.06% | O: 0.27% H: 2.08% C: 1.99%
TAK | $13.85 -0.07% 0.0% |

| 0.87% | O: 0.36% H: 0.0% C: 0.0%
NVS | News | $84.77 0.71% -0.64% |

| 3.9% | O: 2.38% H: 0.0% C: 0.0%
treatment market

Manufacturing

| -1.07% | O: 4.33% H: 0.0% C: -2.44%
SNY | News | $52.67 1.02% -0.32% |

| 3.97% | O: 3.49% H: 0.0% C: 0.0%
ALPMF | News | $16.71 5.56% |

| 6.07% | O: 0.99% H: 0.0% C: -0.5%
ABBV | $154.14 1.08% -1.03% |

| 3.86% | O: 1.57% H: 0.0% C: 0.0%
GLAXF | News | $21.01 -4.46% |

| 0.89% | O: 3.19% H: 2.28% C: -1.81%
AMGN | $245.43 0.79% 0.0% |

| 1.51% | O: 0.92% H: 0.82% C: 0.56%
GSK | News | $43.77 0.97% -0.87% |

| 2.92% | O: 1.79% H: 0.95% C: 0.92%
NVS | News | $84.77 0.71% -0.64% |

| 3.9% | O: 2.38% H: 0.0% C: 0.0%
GLMD | $0.65 10.02% -3.85% |

| 31.58% | O: 1.21% H: 0.0% C: -3.5%
europe growth market

AbbVie Declares Quarterly Dividend
Published: 2022-06-23 (Crawled : 20:00) - prnewswire.com
ABBV | $154.14 1.08% -1.03% |

| 3.86% | O: 1.57% H: 0.0% C: 0.0%

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market to Surpass US$ 20,450.6 Million by 2030 - Coherent Market Insights
Published: 2022-06-22 (Crawled : 19:00) - prnewswire.com
ABBV | $154.14 1.08% -1.03% |

| 4.46% | O: 0.57% H: 0.0% C: 0.0%
GSK | News | $43.77 0.97% -0.87% |

| 4.19% | O: 1.24% H: 0.0% C: 0.0%
ENDP | $0.5226 -26.39% 0.56% |

| 45.17% | O: -2.25% H: 13.16% C: 10.83%
GLAXF | News | $21.01 -4.46% |

| -2.23% | O: -0.14% H: 0.14% C: -2.96%
PFE | News | $50.94 0.55% -0.43% |

| 3.81% | O: 0.43% H: 0.0% C: 0.0%
infections skin market

AbbVie Seeks New Indication for Migraine Drug Qulipta, Drops Deal with Morphic
Published: 2022-06-22 (Crawled : 16:00) - biospace.com/
ABBV | $154.14 1.08% -1.03% |

| 10.17% | O: 2.73% H: 4.44% C: 2.67%
drug for deal migraine

AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine
Published: 2022-06-21 (Crawled : 14:00) - biospace.com/
ABBV | $154.14 1.08% -1.03% |

| 11.8% | O: 1.48% H: 0.0% C: 0.0%
treatment fda expansion drug label for application migraine

AbbVie's Skyrizi Becomes First FDA-Approved IL-23 Inhibitor for Crohn's Disease
Published: 2022-06-20 (Crawled : 12:20) - biospace.com/
ABBV | $154.14 1.08% -1.03% |

| Email alert Add to watchlist
il-23 skyrizi disease for

Outlook on the Antidepressant Drugs Global Market to 2030 - Featuring Alkermes, AbbVie and GlaxoSmithKline Among Others
Published: 2022-06-17 (Crawled : 19:00) - prnewswire.com
ABBV | $154.14 1.08% -1.03% |

| Email alert Add to watchlist
TEVJF | News | $7.575 -9.17% |

| Email alert Add to watchlist
LLY | News S | $323.0 1.69% 0.07% |

| Email alert Add to watchlist
ALKS | $30.29 -0.33% 0.0% |

| Email alert Add to watchlist
market

Biologic Therapy Market Information: By Product and Geography - Global Forecast till 2025
Published: 2022-06-17 (Crawled : 14:00) - prnewswire.com
AZNCF | $131.0 -0.53% |

| 10.32% | O: 1.89% H: 0.0% C: -0.64%
NVS | News | $84.77 0.71% -0.64% |

| 4.1% | O: 0.07% H: 0.0% C: 0.0%
GSK | News | $43.77 0.97% -0.87% |

| 5.5% | O: -0.24% H: 0.0% C: 0.0%
NVSEF | News | $84.85 1.0% |

| 4.91% | O: 0.74% H: 0.52% C: -3.23%
GLAXF | News | $21.01 -4.46% |

| 2.05% | O: 0.01% H: 0.17% C: 0.17%
ABBV | $154.14 1.08% -1.03% |

| 12.97% | O: 1.05% H: 0.0% C: 0.0%
SNYNF | News | $108.84 4.15% |

| 12.02% | O: -1.76% H: 5.75% C: 5.5%
JNJ | News | $176.99 0.03% -0.29% |

| 5.33% | O: 1.35% H: 0.0% C: 0.0%
SNY | News | $52.67 1.02% -0.32% |

| 8.43% | O: 1.39% H: 0.0% C: 0.0%
AZN | $67.02 1.65% -0.48% |

| 10.14% | O: 0.59% H: 0.0% C: 0.0%
therapy market

Global Conjugated Monoclonal Antibodies (mAbs) Market Report 2022: A $12.09 Billion Market by 2026 - Forecast to 2031
Published: 2022-06-17 (Crawled : 13:20) - prnewswire.com
ABBV | $154.14 1.08% -1.03% |

| 12.97% | O: 1.05% H: 0.0% C: 0.0%
NVS | News | $84.77 0.71% -0.64% |

| 4.1% | O: 0.07% H: 0.0% C: 0.0%
NVSEF | News | $84.85 1.0% |

| 4.91% | O: 0.74% H: 0.52% C: -3.23%
report market

SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
Published: 2022-06-17 (Crawled : 12:20) - prnewswire.com
ABBV | $154.14 1.08% -1.03% |

| 12.97% | O: 1.05% H: 0.0% C: 0.0%
il-23 skyrizi fda disease active approval

Global Targeted Drug Delivery Market 2022-2030 with 2021 as the Base Year
Published: 2022-06-17 (Crawled : 12:00) - prnewswire.com
AZNCF | $131.0 -0.53% |

| 10.32% | O: 1.89% H: 0.0% C: -0.64%
SNYNF | News | $108.84 4.15% |

| 12.02% | O: -1.76% H: 5.75% C: 5.5%
BSX | News S | $37.8 0.8% 0.0% |

| 8.0% | O: 1.69% H: 2.14% C: 1.18%
BAX | $65.81 0.86% 0.0% |

| -1.17% | O: -1.77% H: 0.0% C: 0.0%
ABBV | $154.14 1.08% -1.03% |

| 12.97% | O: 1.05% H: 0.0% C: 0.0%
ARWR | $34.56 6.44% 0.0% |

| 22.64% | O: 0.67% H: 7.55% C: 2.64%
SNY | News | $52.67 1.02% -0.32% |

| 8.43% | O: 1.39% H: 0.0% C: 0.0%
AZN | $67.02 1.65% -0.48% |

| 10.14% | O: 0.59% H: 0.0% C: 0.0%
drug year market

Facial Aesthetics Market: USD 1.45 billion Growth from 2020 to 2025 | High Competition in the Market due to the Presence of Region-specific Vendors| Technavio
Published: 2022-06-14 (Crawled : 15:20) - prnewswire.com
BHC | News A | $8.51 -3.62% 0.0% |

| 12.27% | O: -0.26% H: 0.73% C: -2.12%
ABBV | $154.14 1.08% -1.03% |

| 9.4% | O: -1.04% H: 0.87% C: -1.31%
ANIK | $22.51 1.44% 0.0% |

| 10.02% | O: 0.2% H: 0.54% C: -0.1%
growth market

Global Axial Spondyloarthritis Market Research Repoirt 2022: Biopharmaceutical Companies are Trying to Match Themselves with New Technologies in the Market to Improve the Overall System
Published: 2022-06-14 (Crawled : 11:00) - prnewswire.com
ABBV | $154.14 1.08% -1.03% |

| 9.4% | O: -1.04% H: 0.87% C: -1.31%
JNJ | News | $176.99 0.03% -0.29% |

| 4.09% | O: 0.43% H: 0.0% C: 0.0%
BMY | $78.28 -0.53% -1.0% |

| 6.02% | O: -0.4% H: 0.33% C: -0.91%
UCBJY | $43.05 0.78% |

Manufacturing

| 4.19% | O: -0.22% H: 0.0% C: -1.02%
PFE | News | $50.94 0.55% -0.43% |

| 4.47% | O: -2.24% H: 0.0% C: 0.0%
AMGN | $245.43 0.79% 0.0% |

| 3.15% | O: -0.41% H: 0.73% C: -0.54%
TAK | $13.85 -0.07% 0.0% |

| 4.29% | O: -0.04% H: 0.0% C: 0.0%
LLY | News S | $323.0 1.69% 0.07% |

| 11.15% | O: -0.49% H: 0.98% C: 0.56%
research system companies market

Breast Implant Market Forecast Report 2021: USD 437.17 Million Market Growth Opportunity by 2025| Technavio
Published: 2022-06-14 (Crawled : 07:00) - prnewswire.com
ESTA | $56.43 -0.12% -0.27% |

| 1.46% | O: -1.29% H: 0.42% C: -0.24%
ABBV | $154.14 1.08% -1.03% |

| 9.4% | O: -1.04% H: 0.87% C: -1.31%
report implant growth market

Global Cytotoxic Drugs Market Estimated to Reach $14,885.2 Million by 2028 and Grow at 1.2% CAGR in the 2021-2028 Timeframe [202-Pages] | Report by Research Dive
Published: 2022-06-13 (Crawled : 13:20) - prnewswire.com
JNJ | News | $176.99 0.03% -0.29% |

| 3.06% | O: -0.99% H: 0.0% C: 0.0%
ABBV | $154.14 1.08% -1.03% |

| 6.79% | O: -2.38% H: 0.0% C: 0.0%
SNY | News | $52.67 1.02% -0.32% |

| 3.25% | O: -1.69% H: 0.0% C: 0.0%
GSK | News | $43.77 0.97% -0.87% |

| 1.05% | O: -0.52% H: 0.0% C: 0.0%
NVS | News | $84.77 0.71% -0.64% |

| 0.03% | O: -1.86% H: 0.0% C: 0.0%
LLY | News S | $323.0 1.69% 0.07% |

| 7.68% | O: -3.12% H: 0.0% C: 0.0%
GLAXF | News | $21.01 -4.46% |

| -3.73% | O: 1.53% H: 0.0% C: -4.56%
research report market

AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress
Published: 2022-06-11 (Crawled : 16:20) - prnewswire.com
ABBV | $154.14 1.08% -1.03% |

| Email alert Add to watchlist
cd20 duobody trial results

ABBVIE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of AbbVie Inc. - ABBV
Published: 2022-06-11 (Crawled : 04:20) - prnewswire.com
ABBV | $154.14 1.08% -1.03% |

| Email alert Add to watchlist
initiated

← Previous
1
2
3
4
5
6
7
8
9
…
23
24
Next →

USA Holiday (Independence Day) in 4 days

Your saved searches

Save your searches and get alerts when important news are released.

Mentioned Today

ACN | News | $279.81 -1.41% -0.96% |

ALTR | News | $51.79 1.05% 0.0% |

ARQQ | News | $5.6 -0.18% 10.71% |

Information

ATHE | News | $0.6406 -1.45% -1.65% |

BDX | News 4 | $249.34 1.97% 0.0% |

BNPQF | News | $48.11 -3.1% |

Finance

BNPQY | News | $24.69 -1.2% |

Finance and Insurance

BNPZY | News | $ 0% |

Finance and Insurance

BTC | News | $ 0% |

BTGOF | News | $2.35 2.17% |

Communications

CAE | News | $24.13 -2.27% 0.0% |

CALT | News | $17.52 -1.21% 0.0% |

CCC | News | $28.94 0% |

CDNA | News | $22.09 0.78% 0.0% |

CGC | News 4 | $3.5 -3.05% -6.86% |

Process Industries

CLVT | News | $14.13 0.71% 0.0% |

Information

CONE | News | $90.25 0% |

Finance

CRM | News 4 | $170.61 -0.5% -2.09% |

DAO | News | $5.27 -4.87% 0.0% |

ENS | News | $57.69 -1.94% 0.0% |

Producer Manufacturing

ERIC | News | $7.64 -1.8% 1.57% |

Electronic Technology

ESLT | News | $218.6 3.91% 0.64% |

Electronic Technology

FDS | News 4 | $383.1 1.89% 5.0% |

Health Care and Social Assistan...

FLNG | News | $27.21 -1.66% 2.76% |

Energy Minerals

FNCTF | News | $11.8637 3.98% |

Communications

FTRP | News | $0.85 -1.31% |

GBTC | News | $ 0% |

HIL | News | $1.69 3.05% 0.0% |

Industrial Services

HYW | News | $6.75 -1.46% 0.0% |

Finance and Insurance

INAPQ | News | $ 0% |

JCI | News | $48.68 0.5% -0.04% |

Producer Manufacturing

JNJ | News | $176.99 0.03% -0.29% |

KEQU | News 4 | $14.0 0.36% -1.79% |

Producer Manufacturing

KHC | News 4 | $37.98 0.66% -0.24% |

MGNI | News | $9.44 -0.94% -0.32% |

NTES | News | $92.52 -1.28% 0.84% |

NVS | News | $84.77 0.71% -0.64% |

NVSEF | News | $84.85 1.0% |

OKTA | News 4 | $93.36 0.82% 0.0% |

OSCR | News | $4.41 -3.08% 0.0% |

PCRFF | News | $8.217 0.82% |

PCRFY | News | $8.11 -0.61% |

PEGA | News | $49.16 -0.51% 0.0% |

POOL | News | $349.98 -0.88% 0.0% |

Distribution Services

QSR | News | $49.61 1.1% -0.4% |

Consumer Services

RUBI | News | $ 0% |

RYLPF | News | $21.116 -1.44% |

SAP | News | $93.93 -1.61% -5.46% |

SAPGF | News | $93.64 -3.84% |

STZ | News | $243.63 -0.77% 0.0% |

TDOC | News | $34.35 -2.08% -2.48% |

Health Services

TGH | News | $27.22 -2.05% 0.66% |

Finance

UL | News | $45.56 0.51% -0.83% |

UNLYF | News | $45.09 -1.56% |

VRCA | News | $2.17 -6.87% -1.29% |